Component: (Network and Table)
Network
00200 - Statement - Condensed Consolidated Statements of Comprehensive Loss
(http://www.immunomedics.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000722830 (http://www.sec.gov/CIK)
Condensed Consolidated Statements of Comprehensive Loss [Abstract]Period [Axis]
2015-07-01 - 2016-06-30
2014-07-01 - 2015-06-30
2013-07-01 - 2014-06-30
Condensed Consolidated Statements of Comprehensive Loss [Abstract]
 
 
 
Revenues:
 
 
 
Product sales
2,260,994  
2,648,657  
3,140,604  
License fee and other revenues
386,941  
1,250,000  
4,623,333  
Research and development
585,312  
1,754,434  
1,277,668  
Total revenues
3,233,247  
 
5,653,091  
 
9,041,605  
 
Costs and Expenses:
 
 
 
Costs of goods sold
1,159,173  
264,915  
338,572  
Costs of license fee and other revenues
  
1,189,170  
Research and development
53,492,471  
41,735,888  
33,680,158  
Sales and marketing
1,027,139  
768,871  
1,132,921  
General and administrative
6,562,555  
9,102,926  
8,281,025  
Total costs and expenses
62,241,338  
 
51,872,600  
 
44,621,846  
 
Operating loss
(59,008,091) 
 
(46,219,509) 
 
(35,580,241) 
 
Interest expense
(5,479,821) 
(2,090,750) 
 
Interest and other income, net
337,901  
245,705  
55,916  
Foreign currency transaction (loss) gain, net
(39,538) 
(1,188) 
938  
Loss before income tax
(64,189,549) 
 
(48,065,742) 
 
(35,523,387) 
 
Income tax benefit (expense)
5,053,833  
(58,229) 
(7,791) 
Net loss
(59,135,716) 
 
(48,123,971) 
 
(35,531,178) 
 
Less: Net loss attributable to noncontrolling interest
(98,766) 
(121,605) 
(105,352) 
Net loss attributable to Immunomedics, Inc. stockholders
(59,036,950) 
 
(48,002,366) 
 
(35,425,826) 
 
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):
(.62) 
(.51) 
(.42) 
Weighted average shares used to calculate loss per common share, (basic and diluted)
94,770,172  
93,314,872  
84,631,567  
Other comprehensive income (loss), net of tax:
 
 
 
Foreign currency translation adjustments
1,192  
(434,617) 
100,094  
Unrealized gain (loss) on securities available for sale
27,674  
11,688  
(87) 
Other comprehensive income (loss)
28,866  
 
(422,929) 
 
100,007  
 
Comprehensive loss
(59,106,850) 
(48,546,900) 
(35,431,171) 
Less comprehensive loss attributable to noncontrolling interest
(98,766) 
(121,605) 
(105,352) 
Comprehensive loss attributable to Immunomedics, Inc. stockholders
(59,008,084) 
 
(48,425,295) 
 
(35,325,819)